Protein Target Found in HPV-Negative Neck Cancers
Researchers have identified a protein that may drive tumor growth and reduce immune response in certain neck cancers.
Updated on Sept. 23, 2026 in Cancer
A new laboratory study has identified that SUV420H1 protein overexpression occurs in approximately 35% of HPV-negative head and neck squamous cell carcinoma tumors. This protein appears to influence both tumor proliferation and the ability of cancer cells to evade the immune system.
Why it matters
HPV-negative head and neck squamous cell carcinoma is associated with significant morbidity and mortality, creating an urgent need for more effective treatments. Identifying this protein as a potential therapeutic target could lead to better outcomes for patients with these aggressive tumors.
In a preclinical study using human cell lines and syngeneic mouse models, researchers found that SUV420H1 amplification occurs in 35% of HPV-negative HNSCC tumors. The study evaluated cell cycling, proliferation, and immune sensitivity, though these findings remain preliminary.
The details
SUV420H1 is a protein lysine methyltransferase that functions by writing H4K20me3, a chemical modification of DNA packaging proteins. When this protein is depleted, tumor cells show decreased rates of proliferation, cell cycling, and invasion. Furthermore, its removal reduces the presence of protumorigenic granulocytic myeloid-derived suppressor cells, which helps sensitize tumors to anti-PD-1 immunotherapy.
Timeline
September 23, 2026: Findings were published in a scientific article.
Health Landscape
This discovery adds a potential mechanism to improve the effectiveness of anti-PD-1 immunotherapy in tumors that are otherwise resistant. It expands the current focus on the tumor microenvironment as a way to enhance existing standard-of-care treatments.
While these findings are an early step in laboratory science, they highlight the role of specific protein markers in cancer behavior. Patients currently managing an HNSCC diagnosis should discuss with their oncology team whether their tumor has been tested for specific genetic or protein biomarkers.
The takeaway
Targeting SUV420H1 may eventually offer a way to make aggressive neck tumors more responsive to immune-based treatments. For now, focus on adhering to your established care plan and keeping your medical team informed of any changes in your symptoms or health status.
Further reading
For more information on current treatment strategies and emerging research, visit our Cancer section.
Source note: This article includes information reported by Nature.
